Changes in Clinical Manifestations Due to AFLD Retyping Based on the New MAFLD Criteria: An Observational Study Based on the National Inpatient Sample Database

Author:

Feng Xiaoshan12345ORCID,Xuan Ruirui12345,Dong Yingchun12345,Wu Xiaoqin6,Cheng Yiping12345ORCID,Yuan Zinuo12345,Dong Hang12345,Han Junming12345,Zhong Fang12345,Zhao Jiajun12345ORCID,Fan Xiude12345ORCID

Affiliation:

1. Department of Endocrinology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China

2. Shandong Clinical Research Center of Diabetes and Metabolic Diseases, Jinan 250021, China

3. Shandong Institute of Endocrine and Metabolic Diseases, Jinan 250021, China

4. Shandong Engineering Laboratory of Prevention and Control for Endocrine and Metabolic Diseases, Jinan 250021, China

5. Shandong Engineering Research Center of Stem Cell and Gene Therapy for Endocrine and Metabolic Diseases, Jinan 250021, China

6. Northern Ohio Alcohol Center, Department of Inflammation and Immunity, Cleveland Clinic, Cleveland, OH 44196, USA

Abstract

(1) Background: As the introduction of “positive” diagnostic criteria for metabolic dysfunction-associated fatty liver disease (MAFLD) does not exclude alcohol consumption, some patients originally diagnosed with alcoholic fatty liver disease (AFLD) may be diagnosed with dual- etiology fatty liver disease (AFLD&MAFLD), which requires us to urgently explore the impact of the changes in this classification of AFLD on clinical manifestations. (2) Methods: Utilizing data from the Nationwide Inpatient Sample database 2016–2018, a total of 9269 participants with AFLD were selected. With the definition of MAFLD, these patients were further categorized into two groups: single AFLD and AFLD&MAFLD. The primary outcome was the risk of comorbidities and organ failures. The secondary outcomes were the length of stay, total charges, and in-hospital all-cause mortality. (3) Results: The patients with AFLD&MAFLD were older, were predominantly male, and had more comorbidities and organ failures compared to the patients with AFLD. These comorbidities included coronary atherosclerosis, myocardial infarction, cerebrovascular disease, arrhythmia, asthma, chronic obstructive pulmonary disease, and chronic kidney disease (all p values < 0.05). The patients with AFLD&MAFLD were more likely to develop acute and chronic heart and/or kidney failures than those with single AFLD (all p < 0.05). The length of stay and total charges of the patients in the AFLD&MAFLD group were greater than the single AFLD group (p = 0.029 and p < 0.001, respectively). No significant difference in all-cause mortality was observed. (4) Conclusions: The patients with AFLD&MAFLD have more comorbidities and organ failures, longer hospital stays, and higher hospitalization costs than the patients with single AFLD. Hence, patients with dual-etiology fatty liver disease deserve more attention from clinical staff during treatment.

Funder

National Key Research and Development Program of China

National Natural Science Foundation

Natural Science Foundation of Shandong Province

Publisher

MDPI AG

Subject

Clinical Biochemistry

Reference36 articles.

1. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement;Eslam;J. Hepatol.,2020

2. Global multi-stakeholder endorsement of the MAFLD definition;Bugianesi;Lancet Gastroenterol. Hepatol.,2022

3. A new definition for non-alcoholic fatty liver disease;Poniachik;J. Hepatol.,2021

4. Alcoholic liver disease: Pathogenesis and new therapeutic targets;Gao;Gastroenterology,2011

5. Practice Guideline Committee of the American Association for the Study of Liver D, Practice Parameters Committee of the American College of G. Alcoholic liver disease;Dasarathy;Hepatology,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3